- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
ARRY Market Currents
more »
-
April 30 Array Biopharma (ARRY): Q1 EPS -$0.11 beats by $0.04. Revenue of $19M (+7% Y/Y) beats by $1M. (PR)
Comment![Earnings, Healthcare]
ARRY Related Articles
more »
ARRY News
more »
-
at MarketWatch.com (Feb 9, 2012)
-
at MarketWatch.com (Jan 31, 2012)
ARRY Press Releases and Filings
more »
-
Business Wire (May 16, 2012)
-
Business Wire (May 14, 2012)
-
Business Wire (Apr 30, 2012)
-
Business Wire (Apr 30, 2012)
-
Business Wire (Apr 26, 2012)
ARRY Latest Transcript
more »
ARRY Cramer
more »
Currently, there are no Cramer articles on ARRY.
ARRY Instablog posts
more »
ARRY vs. ETF Alternatives
Company Description
We are a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. Our proprietary drug development pipeline includes clinical candidates that are designed... More
